Principal Financial Group Inc I Mab Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$8.27 - $18.43 $2.44 Million - $5.45 Million	-295,462 Reduced 87.18%	43,457 $491,000
Q1 2022 May 09, 2022	SELL	$12.54 - $46.93 $4.06 Million - $15.2 Million	-323,615 Reduced 48.85%	338,919 $5.5 Million
Q4 2021 Feb 09, 2022	SELL	$45.28 - $74.5 $8.44 Million - $13.9 Million	-186,423 Reduced 21.96%	662,534 $31.4 Million
Q3 2021 Nov 09, 2021	BUY	$57.18 - $84.43 $4.84 Million - $7.14 Million	84,594 Added 11.07%	848,957 $61.5 Million
Q2 2021 Aug 10, 2021	BUY	$47.86 - $83.95 $22.8 Million - $40.1 Million	477,321 Added 166.29%	764,363 $64.2 Million

Q1 2021 May 10, 2021	BUY	$44.38 - $63.97 $12.7 Million - $18.4 Million	287,042 New	287,042 $13.9 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.